Publication | Open Access

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

Lymphoid NeoplasiaMedicinePharmacologyClinical TrialsTreatment OptionImmune Checkpoint InhibitorPharmacotherapyImmunotherapyOncologyRituximab Versus Placebo